Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Linavonkibart by Scholar Rock for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Linavonkibart is under clinical development by Scholar Rock and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
Data Insights
Risk adjusted net present value: What is the current valuation of Scholar Rock Holding's Linavonkibart?
Linavonkibart is a monoclonal antibody commercialized by Scholar Rock Holding, with a leading Phase I program in Oropharyngeal Cancer. According...